(Alliance News) - AstraZeneca PLC on Tuesday said its prostate cancer drug candidate Lynparza has received priority review from the US Food & Drug Administration.
The drug, developed and commercialised with New-Jersey based partner Merck & Co Inc, will be reviewed for adult patients in the US with metastatic castration-resistant prostate cancer. Metastatic is when cancer spreads to distant parts of the body.
Lynparza, also known as Olaparib, since 2014 has been approved for the treatment of some forms of ovarian cancer in adults in the US and EU.
The priority review will gauge the efficacy of Lynparza in combination with both abiraterone and prednisone, or solely with prednisolone. Abiraterone is a prostate cancer medication while prednisolone is used to treat a plethora of diseases such as cancer, high blood calcium and multiple sclerosis.
Prostate cancer is the second most common cancer in male patients in the US with about 35,000 people projected to die from it in 2022, AstraZeneca explained, citing figures from Cancer.org.
AstraZeneca shares were slightly higher at 10,964.00 pence each in London on Tuesday morning.
By Tom Budszus; tombudszus@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)
